Patents Examined by Prema Mertz
  • MCP1-Ig fusion variants
    Patent number: 8524217
    Abstract: The present invention provides, in part, MCP1-Ig fusion polypeptides exhibiting surprisingly beneficial properties as well as methods for treating various diseases (e.g., inflammatory diseases) by administering any of such fusions.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: September 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Leonard G. Presta, Chuan-Chu Chou
  • Treating inflammatory diseases with antibodies that inhibit fractalkine-CXCR1 interaction
    Patent number: 8518401
    Abstract: A therapeutic agent for an inflammatory disease comprising an antibody or a CX3CR1 antagonist that inhibits an interaction of fractalkine and CX3CR1 is provided.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: August 27, 2013
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshikazu Kuboi, Toshio Imai, Miyuki Nishimura, Keiko Mizuno
  • Methods of inhibiting proliferation or immunoglobulin production of B cells using human tumor necrosis factor receptor TR-17 polypeptides
    Patent number: 8518389
    Abstract: The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for producing the same. The invention further relates to methods of killing cells using the antibodies of the invention.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: August 27, 2013
    Assignee: Human Genome Sciences
    Inventors: Steven M. Ruben, Kevin P. Baker
  • Tmem27 antibody
    Patent number: 8512704
    Abstract: The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: August 20, 2013
    Assignee: Genentech, Inc.
    Inventors: Kerstin Jahn-Hofmann, Sannah Zoffmann Jensen, Hugues Matile, Cristiano Migliorini, Haiyan Wang
  • Engineered anti-IL-23p19 antibodies
    Patent number: 8513389
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: August 20, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Antibodies to matrix metalloproteinase 9
    Patent number: 8501916
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 6, 2013
    Assignee: Gilead Biologics, Inc.
    Inventors: Scott McCauley, Maria Vaysberg
  • Antibodies to high mobility group-1(HMGB1) B-box polypeptides
    Patent number: 8501173
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: August 6, 2013
    Assignees: The General Hospital Corporation, The Feinstein Institute for Medical Research, University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
  • Neutralizing anti-CCL20 antibodies
    Patent number: 8491901
    Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: July 23, 2013
    Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
  • Antibody to human IL-3 receptor alpha chain
    Patent number: 8492119
    Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: July 23, 2013
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Tomonori Tawara, Shinichiro Takayanagi, Yoshimasa Inagaki
  • Methods for treating acute myeloid leukemia with diphtheria toxin-interleukin-3 conjugates
    Patent number: 8470307
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: June 25, 2013
    Assignee: Scott & White Memorial Hospital
    Inventor: Arthur E. Frankel
  • Nucleic acid encoding antibody to human IL-22
    Patent number: 8470993
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: June 25, 2013
    Assignees: Wyeth LLC, MedImmune Limited
    Inventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralph R. Minter
  • Method of treating inflammation by administering human IL-1B antibodies
    Patent number: 8465744
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1?, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: June 18, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew George Popplewell
  • Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
    Patent number: 8454956
    Abstract: The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: June 4, 2013
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Interleukin-1 muteins linked to virus-like particles to treat IL-1 associated diseases
    Patent number: 8449874
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 mutein. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1 mutein linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory diseases, and chronic autoimmune diseases, genetic diseases and cardiovascular diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: May 28, 2013
    Assignee: Cytos Biotechnology AG
    Inventors: Martin F. Bachmann, Gunther Spohn, Alain Tissot
  • Methods of treating lupus nephritis using antibodies against monocyte chemotactic proteins
    Patent number: 8431125
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: April 30, 2013
    Assignee: Biogen Idec MA, Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
    Patent number: 8425897
    Abstract: The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: April 23, 2013
    Assignee: Immutep S.A.
    Inventors: Karin Jooss, Betty Li, Frederic Triebel
  • Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
    Patent number: 8415301
    Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: April 9, 2013
    Assignee: Corthera, Inc.
    Inventors: Elaine Unemori, Sam L Teichman, Gad Cotter, Dennis R Stewart, Martha J Whitehouse
  • Method for inducing angiogenesis in an infarcted heart by administering a coiled coil chimeric molecule
    Patent number: 8414877
    Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: April 9, 2013
    Assignee: Aprogen, Inc.
    Inventors: Gou Young Koh, Chung-Hyun Cho
  • Methods and compositions for preventing adhesion
    Patent number: 8398973
    Abstract: This invention provides methods and compositions for preventing post-surgical adhesion formation based on use of an interleukin-16 (IL-16) antagonist, including an IL-16 antagonist peptide and/or an IL-16 antagonist antibody.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: March 19, 2013
    Assignee: Trustees of Boston University
    Inventors: William W. Cruikshank, David M. Center
  • Method of using heparin binding motif for treating asthma
    Patent number: 8399416
    Abstract: The present invention is for an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 9 and using the peptide for treating asthma by reducing cytotoxicity of eosinophil derived toxins in bronchial epithelial cells of the subject suffers from asthma. The method comprises preparing a pharmaceutical composition having the peptide of SEQ ID NO: 9 and administering an effective amount of the composition to the subject.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: March 19, 2013
    Assignee: National Tsing Hua University
    Inventors: Margaret Dah-Tsyr Chang, Tan-chi Fan, Shu-Chuan Lin